echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Boan Bio-Boyounuo® (bevacizumab injection) is officially listed as a patient aid item...

    Boan Bio-Boyounuo® (bevacizumab injection) is officially listed as a patient aid item...

    • Last Update: 2021-06-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The anti-tumor biopharmaceutical Boyouno® (bevacizumab injection) developed by Boan Bio, a subsidiary of Luye Pharmaceutical Group, was officially launched in China on June 5.


    Bevacizumab injection is a representative anti-tumor angiogenesis drug.


    As a biosimilar of Bevacizumab, Boyouno® has undergone a head-to-head comparison with the original drug in two key clinical studies, that is, a pharmacokinetic PK comparison study in healthy volunteers.


    "In clinical research, Boyouno® has shown good efficacy and safety, which is highly similar to the original drug.


    In recent years, the number of cancer cases in my country has been on the rise.


    Anti-angiogenic drugs are one of the indispensable methods in the treatment of malignant tumors.


    Professor Liang Jun from Peking University International Hospital said: “Bevacizumab can be used in combination with many other treatment methods, and its combined treatment model has many advantages, and it continues to play a role in the treatment of non-small cell lung cancer, colorectal cancer and other malignant tumors.


    In order to further improve the accessibility and affordability of treatment for patients, Boan Bio and Beijing Kangmeng Charity Foundation jointly launched the "Boyouno® Patient Relief Project".


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.